Quadrant Capital Group LLC Madrigal Pharmaceuticals, Inc. Transaction History
Quadrant Capital Group LLC
- $2.65 Billion
- Q1 2025
A detailed history of Quadrant Capital Group LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Quadrant Capital Group LLC holds 2,621 shares of MDGL stock, worth $748,898. This represents 0.03% of its overall portfolio holdings.
Number of Shares
2,621
Previous 22
11813.64%
Holding current value
$748,898
Previous $6,000
14366.67%
% of portfolio
0.03%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding MDGL
# of Institutions
367Shares Held
23.3MCall Options Held
979KPut Options Held
459K-
Janus Henderson Group PLC London, X02.21MShares$630 Million0.42% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.1MShares$600 Million39.89% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.02MShares$578 Million10.84% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$570 Million10.82% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$564 Million7.8% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $4.89B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...